Zoetis (NYSE:ZTS)‘s stock had its “buy” rating reiterated by equities researchers at Citigroup in a note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $98.00 target price on the stock, up from their previous target price of $85.00. Citigroup’s price target would suggest a potential upside of 14.69% from the company’s current price.
Several other research firms have also issued reports on ZTS. Jefferies Group reaffirmed a “buy” rating and issued a $96.00 price target on shares of Zoetis in a report on Friday, April 13th. Credit Suisse Group lifted their price target on shares of Zoetis from $83.00 to $89.00 and gave the stock an “outperform” rating in a report on Thursday, April 5th. Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Thursday, January 11th. ValuEngine upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Piper Jaffray set a $88.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $81.61.
NYSE ZTS opened at $85.45 on Thursday. The company has a debt-to-equity ratio of 2.77, a quick ratio of 2.55 and a current ratio of 3.85. Zoetis has a 12-month low of $54.00 and a 12-month high of $86.38. The firm has a market capitalization of $41,717.26, a price-to-earnings ratio of 35.60, a PEG ratio of 1.91 and a beta of 0.96.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the company earned $0.47 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. sell-side analysts anticipate that Zoetis will post 3.04 EPS for the current year.
In related news, insider Heidi C. Chen sold 7,383 shares of the business’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $84.71, for a total transaction of $625,413.93. Following the completion of the transaction, the insider now directly owns 20,162 shares in the company, valued at $1,707,923.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Roman Trawicki sold 8,568 shares of the business’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $83.10, for a total transaction of $712,000.80. Following the transaction, the insider now owns 11,457 shares of the company’s stock, valued at $952,076.70. The disclosure for this sale can be found here. Insiders have sold 112,952 shares of company stock valued at $9,219,843 over the last 90 days. 0.35% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ZTS. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Zoetis during the fourth quarter valued at $108,000. Steward Partners Investment Advisory LLC acquired a new position in Zoetis during the third quarter valued at $114,000. We Are One Seven LLC acquired a new position in Zoetis during the fourth quarter valued at $120,000. Premia Global Advisors LLC acquired a new position in Zoetis during the fourth quarter valued at $122,000. Finally, Icon Wealth Partners LLC acquired a new position in Zoetis during the fourth quarter valued at $127,000. Institutional investors own 92.33% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/21/zoetis-zts-stock-rating-reaffirmed-by-citigroup.html.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.